Literature DB >> 21738286

ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.

J H Beigel1.   

Abstract

The recent pandemic of H1N1 has demonstrated the potential vulnerability of the human population to novel influenza viruses. While there is recent increased interest and effort in developing effective anti-influenza agents, few new products have entered clinical studies. This review will highlight the limited armamentarium of licensed influenza agents, and discuss novel compounds and strategies that have entered clinical studies and may therefore be imminently available to the treating clinician.

Entities:  

Year:  2010        PMID： 21738286      PMCID： PMC3129656          DOI： 10.1358/dof.2010.035.05.1487081

Source DB:  PubMed          Journal:  Drugs Future        ISSN： 0377-8282            Impact factor:   0.148


  73 in total

1.  [Experience in treating influenza with dry anti-influenza serum of Smorodintsev; preliminary report].

Authors:  A I BEREZINA
Journal:  Sov Med       Date:  1956-01

2.  Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Authors:  Thomas C Luke; Edward M Kilbane; Jeffrey L Jackson; Stephen L Hoffman
Journal:  Ann Intern Med       Date:  2006-08-29       Impact factor: 25.391

3.  Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.

Authors:  Luis Barroso; John Treanor; Larisa Gubareva; Frederick G Hayden
Journal:  Antivir Ther       Date:  2005

4.  Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

5.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Authors:  F G Hayden; A D Osterhaus; J J Treanor; D M Fleming; F Y Aoki; K G Nicholson; A M Bohnen; H M Hirst; O Keene; K Wightman
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

6.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

7.  CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.

Authors:  Makoto Yamashita; Takanori Tomozawa; Masayo Kakuta; Akane Tokumitsu; Hatsumi Nasu; Shuku Kubo
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.

Authors:  Donald F Smee; Brett L Hurst; Min-Hui Wong; Kevin W Bailey; E Bart Tarbet; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

9.  Enhancement of activity against influenza viruses by combinations of antiviral agents.

Authors:  F G Hayden; R G Douglas; R Simons
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

10.  In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.

Authors:  Kazumi Takahashi; Yousuke Furuta; Yoshiko Fukuda; Masako Kuno; Tomoko Kamiyama; Kyo Kozaki; Nobuhiko Nomura; Hiroyuki Egawa; Shinzaburo Minami; Kimiyasu Shiraki
Journal:  Antivir Chem Chemother       Date:  2003-09
View more
  4 in total

1.  Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.

Authors:  Olivia Perwitasari; Xiuzhen Yan; Scott Johnson; Caleb White; Paula Brooks; S Mark Tompkins; Ralph A Tripp
Journal:  Antimicrob Agents Chemother       Date:  2012-11-05       Impact factor: 5.191

2.  #Nitrosocarbonyls 1: antiviral activity of N-(4-hydroxycyclohex-2-en-1-yl)quinoline-2-carboxamide against the influenza A virus H1N1.

Authors:  Dalya Al-Saad; Misal Giuseppe Memeo; Paolo Quadrelli
Journal:  ScientificWorldJournal       Date:  2014-12-31

3.  Model-based simulation and prediction of an antiviral strategy against influenza A infection.

Authors:  Kye-Yeon Hur; Joon-Young Moon; Seung-Hwan Kim; Joo-Yeon Yoo
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

4.  siRNA Genome Screening Approaches to Therapeutic Drug Repositioning.

Authors:  Olivia Perwitasari; Abhijeet Bakre; S Mark Tompkins; Ralph A Tripp
Journal:  Pharmaceuticals (Basel)       Date:  2013-01-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.